Biopharma financings during the second quarter of 2022 reached $12.5bn. The largest was by Blueprint Medicines Corporation (precision therapies for cancer and blood disorders) through an arrangement with Sixth Street, which will provide $660m in debt financing through a $400m senior secured credit facility ($150m drawn up front) and a $260m potential credit facility.
The deal also has a royalty sale provision for another $250m in cash up front in exchange for future royalties...